A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
A Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Paclitaxel Injection as Second Line Treatment for Small Cell Lung Cancer(SCLC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Jia Song
- Phone Number: +86 15921737659
- Email: song.j@biotheus.com
Study Locations
-
-
-
Beijing, China
- Peking University Cancer Hospital
-
Changchun, China
- Jilin Provincial Tumor Hospital
-
Changsha, China
- Hunan Cancer Hospital
-
Chengdu, China
- Sichuan Provincial People's Hospital
-
Hangzhou, China
- Zhejiang Provincial People's Hospital
-
Harbin, China
- Harbin Medical University Cancer Hospital
-
Jinan, China
- Shandong Cancer Hospital
-
Nanchang, China
- The First Affiliated Hospital of Nanchang University
-
Shanghai, China
- Shanghai Pulmonary Hospital
-
Xi'an, China
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Zhengzhou, China
- Henan Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent form before any trial-related processes;
- Age ≥18 years;
- Histologically or cytologically confirmed SCLC;
- Advanced SCLC who failed first-line platinum-based chemotherapy with or without checkpoint inhibitors;
- Have adequate organ function;
- The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;
- Life expectancy of ≥12 weeks;
- Had at least one measurable tumor lesion according to RECIST v1.1.
Exclusion Criteria:
- History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;
- Evidence and history of severe bleeding tendency;
- History of severe cardiovascular diseases within 6 months;
- Current presence of severe superior vena cava syndrome and spinal cord compression;
- Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
- History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation;
- History of alcohol abuse, psychotropic substance abuse or drug abuse;
- Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome;
- Pregnant or lactating women;
- Other conditions considered unsuitable for this study by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PM8002+Paclitaxel
Subjects will be administered with PM8002 plus Paclitaxel via intravenously (IV) Q3W for 5 cycles, followed by PM8002 until disease progression or intolerable toxicity for a maximum of 2 years.
|
IV infusion
IV infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment related adverse events (TRAEs)
Time Frame: Up to 30 days after last treatment
|
The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0
|
Up to 30 days after last treatment
|
|
Objective Response Rate
Time Frame: Up to approximately 2 years
|
Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.
|
Up to approximately 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease control rate (DCR)
Time Frame: Up to approximately 2 years
|
DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1.
|
Up to approximately 2 years
|
|
Duration of response (DoR)
Time Frame: Up to approximately 2 years
|
DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1) or death due to any cause, whichever occurs first.
|
Up to approximately 2 years
|
|
Progression free survival (PFS)
Time Frame: Up to approximately 2 years
|
PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST v1.1).
|
Up to approximately 2 years
|
|
Overall survival (OS)
Time Frame: Up to approximately 2 years
|
OS is the time from the date of first dosing date to death due to any cause.
|
Up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ying Cheng, Jilin Provincial Tumor Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PM8002-B002C-SCLC-R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.